NN6 NanoRepro AG

1.544USD1.405 EUR · XETRA-3.77%Mkt Cap: 19.48M USDP/E: —

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas…

Institutional holders1 on file

Key Statistics

Company
Market Cap19.48M USD
Enterprise Value14.27M USD
Revenue (TTM)4.46M USD
Gross Profit3.24M USD
Net Income (TTM)-2.25M USD
Revenue/Share0.32 USD
Last Price1.544 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryDE
SectorHealthcare
IndustryDiagnostics & Research
ISINDE0006577109
Valuation
P/E (Trailing)—
P/E (Forward)-46.83
PEG—
EV/EBITDA-7.13
EV/Revenue3.20
P/S4.36
P/B0.52
EPS (TTM)-0.15 USD
EPS (Forward)-0.03 USD
52W Range
1.4409% of range2.638
52W High2.638 USD
52W Low1.440 USD
Profitability
Gross Margin63.38%
Oper. Margin-45.71%
EBITDA Margin-44.85%
Profit Margin-44.02%
ROE-5.36%
ROA-5.24%
ROIC—
ROCE-8.91%
Growth
Revenue Growth-11.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF10.84M USD
CapEx (TTM)442.54K USD
FCF Margin—
FCF Yield—
Net Debt-7.20M USD
Net Debt/EBITDA3.60
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio19.84
Quick Ratio18.04
Book Value/Sh2.95 USD
Cash/Share0.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio160.81%
Ex-Div DateJun 16, 2023
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.919 USD
Upside (mean)+218.5%
Target Range4.836 USD – 5.001 USD
4.836+218.5% to mean5.001
# Analysts2
Ownership
Shares Out.12.61M
Float—
Insiders1.82%
Institutions8.06%
Technical
SMA 501.801 (-14.2%)
SMA 2001.876 (-17.7%)
Beta0.55
S&P 52W Chg8.68%
Avg Vol (30d)7.75K
Avg Vol (10d)14.27K
Technical Indicators
RSI (14)33.9
MACD-0.0703
MACD Signal-0.0636
MACD Hist.-0.0068
BB Upper1.849 USD
BB Middle1.664 USD
BB Lower1.480 USD
BB Width22.22%
ATR (14)0.0878 USD
Vol Ratio (20d)0.17x

About NanoRepro (ETR: NN6)

›

NanoRepro (ETR: NN6) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 20 employees.

The shares were at 1.405 EUR on 20 November 2026, down 9.4% over 52 weeks. Its 52-week range is 1.310 EUR to 2.400 EUR: the price is 41.5% below the high and 7.3% above the low.

Its market capitalisation is 17.72M EUR.

NanoRepro reports return on equity of -5.4%, an operating margin of -45.7% and revenue down 11.3% year over year.

It holds more cash than debt, a net cash position of 6.55M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 4.475 EUR is 218.5% above the current price.